forbes.com
🌐 85% Global Worthiness
OSE Immunotherapeutics Launches Global Phase 3 Trial for Cancer Vaccine
OSE Immunotherapeutics, a French biotech firm, launched a global Phase 3 trial for its cancer vaccine Tedopi, securing \$9.3 million in public funding and partnerships with AbbVie and Boehringer Ingelheim, resulting in a 66% stock increase over the past year.
OSE Immunotherapeutics Launches Global Phase 3 Trial for Cancer Vaccine
OSE Immunotherapeutics, a French biotech firm, launched a global Phase 3 trial for its cancer vaccine Tedopi, securing \$9.3 million in public funding and partnerships with AbbVie and Boehringer Ingelheim, resulting in a 66% stock increase over the past year.
Progress
48% Bias Score
Good Health and Well-being